NCT05352867View on ClinicalTrials.gov

Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

June 23, 2022

Study Completion Date

June 21, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

SARS-CoV-2 (LVRNA009) 50μg group

50μg/person

BIOLOGICAL

SARS-CoV-2 (LVRNA009) 100μg group

100μg/person

OTHER

Placebo

0.5ml/person

Trial Locations (2)

410028

Outpatient Department of Hunan Provincial Center For Disease Control And Prevention, Changsha

411228

Xiangtan Center For Disease Control And Prevention, Xiangtan

All Listed Sponsors
collaborator

Hunan Provincial Center for Disease Control and Prevention

OTHER

lead

AIM Vaccine Co., Ltd.

INDUSTRY